Normal “heart” in Parkinson’s disease: Is this a distinct clinical phenotype?
Objective: The aim of this study was to investigate whether non-motor manifestations of Parkinson’s disease (PD) differ between patients with normal and abnormal myocardial metaiodobenzylguanidine (MIBG)…DaTscan in clinical evaluation of Multiple System Atrophy
Objective: To explore accuracy of DaTscanTM Ioflupane I123 Injection (DaTscan) in a multiple system atrophy (MSA) cohort Background: There are isolated cases of normal DaTscan in neuropathologically confirmed MSA-cerebellar subtype (MSA-C)…Neuroimaging studies in familial forms of Parkinson’s disease: A systematic review
Objective: We aim to systematically review the current status of MRI, PET and SPECT imaging in asymptomatic (aPD) and symptomatic (sPD) genetic carriers of PD.…Progression to Parkinson’s disease in carriers of LRRK2 G2019S mutation: a 4-year prospective study with serial dopamine transporter imaging
Objective: To assess whether any of the biomarkers studied (UPDRS-III, SN echogenicity, UPSIT and DaT-SPECT) in a baseline evaluation of a cohort of LRRK2 G2019S asymptomatic…Clinical Criteria for Subtyping Parkinson’s Disease: Differences in imaging and CSF biomarkers and longitudinal progression
Objective: To introduce a new practical classification method to assign individuals with Parkinson’s disease (PD) into distinct subtypes using baseline dataset, then to compare neuroimaging,…Relationship between non-motor symptoms and dopamine transporter activity in Parkinson’ s disease
Objective: We investigated whether dopamine transporter single-photon emission computed tomography (DAT-SPECT) binding correlates to non-motor symptoms in patients with Parkinson’s disease (PD). Background: DAT-SPECT binding…99mTc-TRODAT-1 SPECT imaging in early and late onset Parkinson’s disease.
Objective: In this study we tried to determine the TRODAT SPECT findings in EOPD as compared to LOPD. Background: 99mTc-TRODAT-1, which binds to the dopamine…The combination of the MIBG myocardial scintigraphy and DATSPECT contributes to the diagnosis of PD and other related disorders.
Objective: To evaluate MIBG and DAT SPECT for the diagnosis of Parkinson’s disease (PD) and related disorders, we performed 123I-meta-iodobenzylguanzylguanidine (MIBG) myocardial scintigraphy and (123I)-FP-CIT…SPECT imaging of striatal DAT availability in Parkinson’s: changes over time and relevance to dyskinesias
Objective: This study was designed to explore in Parkinson’s disease (PD) the role of dopamine transporter (DAT)-specific single photon emission computed tomography (SPECT) imaging as a…A neuroimaging-based model for disease progression in Parkinson’s disease
Objective: We model the rate of disease progression over 4 years in subjects with Parkinson’s disease based on neuroimaging features acquired at baseline. Background: DaTSCAN…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- 16
- Next Page »